ÂÜÀòÂÒÂ×

Hesham Ismail HAMED serves as the Chief Scientific Officer, Co-Founder, and Board Member at Adoram Therapeutics since June 2022. Concurrently, multiple roles at the University of Geneva include Collaborateur Scientifique II since March 2009, where responsibilities encompass leading drug discovery and development activities, managing research teams, and conducting teaching at various academic levels. Previous roles include Maître assistant focusing on in vivo drug candidate development for immuno-oncology, Postdoctoral Fellow working on Duchenne muscular dystrophy research, and consulting positions at Skyhawk Therapeutics and Novartis Institutes for BioMedical Research. Education includes a Ph.D. in Pharmacology from the University of Geneva, a Master of Science in Pharmaceutical Sciences from Cairo University, and a Bachelor of Science in Pharmaceutical Sciences from Cairo University.